AU2003233780A1 - Novel glucagon antagonists/inverse agonists - Google Patents

Novel glucagon antagonists/inverse agonists

Info

Publication number
AU2003233780A1
AU2003233780A1 AU2003233780A AU2003233780A AU2003233780A1 AU 2003233780 A1 AU2003233780 A1 AU 2003233780A1 AU 2003233780 A AU2003233780 A AU 2003233780A AU 2003233780 A AU2003233780 A AU 2003233780A AU 2003233780 A1 AU2003233780 A1 AU 2003233780A1
Authority
AU
Australia
Prior art keywords
inverse agonists
glucagon antagonists
novel glucagon
novel
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003233780A
Inventor
Carsten Behrens
Paw Bloch
Inge Thoger Christensen
Anker Steen Jorgensen
Janos Kodra Kodra
Jesper Lau
Peter Madsen
Poul Enrico Nielsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU2003233780A1 publication Critical patent/AU2003233780A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2003233780A 2002-06-27 2003-05-27 Novel glucagon antagonists/inverse agonists Abandoned AU2003233780A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200201006 2002-06-27
DKPA200201006 2002-06-27
DKPA200201927 2002-12-17
DKPA200201927 2002-12-17
PCT/DK2003/000350 WO2004002480A1 (en) 2002-06-27 2003-05-27 Novel glucagon antagonists/inverse agonists

Publications (1)

Publication Number Publication Date
AU2003233780A1 true AU2003233780A1 (en) 2004-01-19

Family

ID=30001779

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003233780A Abandoned AU2003233780A1 (en) 2002-06-27 2003-05-27 Novel glucagon antagonists/inverse agonists

Country Status (4)

Country Link
EP (1) EP1519723A1 (en)
JP (1) JP2006500325A (en)
AU (1) AU2003233780A1 (en)
WO (1) WO2004002480A1 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004030318D1 (en) 2003-01-27 2011-01-13 Merck Sharp & Dohme SUBSTITUTED PYRAZOLE, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND APPLICATION METHOD
CN102584813B (en) 2003-05-14 2016-07-06 Ngc药物公司 Compound and the purposes in regulating amyloid beta thereof
WO2005118542A1 (en) * 2004-05-28 2005-12-15 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
US7816557B2 (en) * 2004-06-14 2010-10-19 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
ATE468853T1 (en) * 2004-07-22 2010-06-15 Merck Sharp & Dohme SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE THEREOF
US20060160869A1 (en) * 2005-01-05 2006-07-20 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
CN101115735B (en) * 2005-02-11 2013-01-09 伊莱利利公司 Glucagon receptor antagonists, preparation and therapeutic uses
WO2006102067A1 (en) 2005-03-21 2006-09-28 Merck & Co., Inc. Substituted aryl and heteroaryl derivatives
AU2006229904A1 (en) 2005-03-30 2006-10-05 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
US7709658B2 (en) 2005-07-26 2010-05-04 Merck Sharp & Dohme Corp. Process for synthesizing a substituted pyrazole
TW200745031A (en) 2005-10-13 2007-12-16 Merck & Co Inc Acyl indoles, compositions containing such compounds and methods of use
JP5140597B2 (en) * 2005-10-21 2013-02-06 メルク・シャープ・エンド・ドーム・コーポレイション Potassium channel inhibitor
CA2629223C (en) 2005-11-17 2013-08-06 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
EP1951661B1 (en) 2005-11-17 2012-08-08 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
DK1951659T3 (en) 2005-11-18 2010-10-11 Lilly Co Eli Glucagon Receptor Antagonists, Preparation and Therapeutic Use thereof
US8691856B2 (en) 2005-11-22 2014-04-08 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
WO2007120284A2 (en) 2005-11-23 2007-10-25 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
US7989472B2 (en) 2006-03-23 2011-08-02 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
CA2650619A1 (en) 2006-05-16 2007-11-29 Merck And Co., Inc. Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
TW200821284A (en) 2006-10-03 2008-05-16 Merck & Co Inc Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
KR20190126460A (en) 2007-02-09 2019-11-11 메타베이시스 테라퓨틱스, 인크. Novel antagonists of the glucagon receptor
JP5450083B2 (en) * 2007-11-01 2014-03-26 武田薬品工業株式会社 Heterocyclic compounds
AU2009220615B2 (en) * 2008-03-05 2013-12-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
AU2009246424A1 (en) 2008-05-16 2009-11-19 Schering Corporation Glucagon receptor antagonists, compositions, and methods for their use
JP5502076B2 (en) 2008-06-05 2014-05-28 グラクソ グループ リミテッド New compounds
JP5508400B2 (en) 2008-06-05 2014-05-28 グラクソ グループ リミテッド Benzpyrazole derivatives as inhibitors of PI3 kinase
ATE552255T1 (en) 2008-06-05 2012-04-15 Glaxo Group Ltd 4-AMINOINDAZOLES
PL2799428T3 (en) 2008-08-13 2017-05-31 Metabasis Therapeutics, Inc. Glucagon antagonists
WO2010066682A1 (en) * 2008-12-08 2010-06-17 Euroscreen S.A. Compounds, pharmaceutical composition and methods for use in treating metabolic disorders
WO2010102958A1 (en) 2009-03-09 2010-09-16 Glaxo Group Limited 4-oxadiazol-2 -yl- indazoles as inhibitors of p13 kinases
PL2424864T3 (en) 2009-04-30 2015-05-29 Glaxo Group Ltd Oxazole substituted indazoles as pi3-kinase inhibitors
WO2011027849A1 (en) * 2009-09-04 2011-03-10 武田薬品工業株式会社 Heterocyclic compound
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
MX2013006768A (en) 2010-12-23 2013-07-22 Pfizer Glucagon receptor modulators.
DK2673260T3 (en) 2011-02-08 2016-10-10 Pfizer Glucagonreceptormodulator
WO2012170951A2 (en) * 2011-06-10 2012-12-13 Calcimedica, Inc. Compounds that modulate intracellular calcium
US20120316182A1 (en) 2011-06-10 2012-12-13 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2734503B1 (en) * 2011-07-22 2015-09-16 Pfizer Inc. Quinolinyl glucagon receptor modulators
US9856240B2 (en) 2011-10-19 2018-01-02 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP3065736B1 (en) 2013-11-04 2018-11-14 Merck Sharp & Dohme Corp. Glucagon receptor antagonist compounds, compositions thereof, and methods of use
EP3154956A4 (en) 2014-06-12 2018-01-17 Ligand Pharmaceuticals, Inc. Glucagon antagonists
TW202003453A (en) 2018-02-13 2020-01-16 美商利根德製藥公司 Glucagon receptor antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2411552A1 (en) * 2000-06-23 2002-01-03 Novo Nordisk A/S Glucagon antagonists/inverse agonists
WO2002040444A1 (en) * 2000-11-17 2002-05-23 Novo Nordisk A/S Glucagon antagonists/inverse agonists

Also Published As

Publication number Publication date
EP1519723A1 (en) 2005-04-06
WO2004002480A1 (en) 2004-01-08
JP2006500325A (en) 2006-01-05

Similar Documents

Publication Publication Date Title
AU2003233780A1 (en) Novel glucagon antagonists/inverse agonists
AU2003236205A1 (en) Glucagon antagonists/inverse agonists
AU2002365622A1 (en) Novel glucagon antagonists
IL163928A0 (en) Pyridinoylpiperidines as 5-htf agonists
AU2003290700A1 (en) Farnesoid x receptor agonists
AU2002347022A1 (en) Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
AU2003224111A1 (en) Substituted pyrazolo-pyrimidine-4-ones
IL165841A0 (en) Mchir antagonists
AU2002341834A1 (en) Antagonists
AU2001255798A1 (en) Glucagon antagonists
AU2002223501A1 (en) Glucagon antagonists/inverse agonists
AU2003243637A1 (en) Cannabinoid receptor agonists
WO2003072535A8 (en) Substituted hydroxyethylamines
AU2003238043A1 (en) Substituted imidazotriazines
AU2002223500A1 (en) Glucagon antagonists/inverse agonists
IL173521A0 (en) Substituted 2 - carbonylamino - 6 piperidinaminopyidines and substituted 1 - carbonylamino - 3 - piperidinaminobenzenes as 5 - th1f agonists
AU2003245984A1 (en) Hetero-cyclicaly substituted imidazotriazines
AU2002951705A0 (en) Reflectometry
GB0211257D0 (en) Novel heterocycles
AU2003291959A1 (en) Novel glucagon antagonists
AU2003303543A1 (en) Agonist antibody against heteroreceptor
AU2002351730A1 (en) Glucagon receptor antagonists/inverse agonists
AU2003294900A1 (en) Substituted 5-aminomethyl-1h-pyrrole-2-carboxamides
AU2003248356A1 (en) Beta3-adrenergic receptor agonists
AU2003212366A1 (en) Substituted 4-aminocyclohexanols

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase